Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $81 from $48 and keeps an Equal Weight rating on the shares. Early ARO-INHBE and ARO-ALK7 monotherapy data provide further validation of a target for fat loss and highlight potential in obesity, the analyst tells investors. The firm views early data as “promising,” with potential for obesity to emerge as another key value driver, the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead price target raised to $80 from $60 at Chardan
- Arrowhead announces offerings of convertible senior notes and common stock
- Arrowhead Reports Promising Interim Data for Obesity RNAi Trials
- Clear Street keeps Buy on Wave Life Sciences after Arrowhead data
- H.C. Wainwright says initial Phase 1/2a data de-risk Arrowhead obesity franchise